A French firm has secured approval from the European Food Safety Authority’s (EFSA’s) Panel on Dietetic Products, Nutrition and Allergies (NDA) for its artichoke leaf extract-based herbal formulation, Limicol®, that evidently can reduce cholesterol. Stating that limited evidence backed claims that any of the “other food constituents in Limicol®, including policosanols and artichoke leaf extract, exert an LDL-cholesterol-lowering effect in humans on their own and that at the proposed conditions of use no evidence has been provided for an LDL-cholesterol-lowering effect of any of the food constituents in Limicol®, or as to how the ingredients individually or in any combination could contribute to the claimed effect,” the panel nevertheless determined that a “cause and effect relationship” has been established between the consumption of the combination of artichoke leaf dry extract standardised in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, OPC from French maritime pine bark, garlic dry extract standardised in allicin, d-α-tocopheryl hydrogen succinate, riboflavin and inositol hexanicotinate in in Limicol®, and a reduction in blood LDL-cholesterol concentrations.